PSMB9 has been investigated as molecular subgroups for therapy selection in prostate cancer, which had significantly lower mRNA level in malignant compared to nonmalignant prostate tissue and were even lower in bone metastasis tissue 38. This evidence concerns the gene PSMB9 and prostate cancer.